ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia
- Author(s)
- Hourigan, CS; Beugelink, L; Othman, J; Gui, G; Ivey, A; Dillon, R; Thiede, C; Levis, MJ; Dillon, LW; Wei, AH; Tiong, IS; Loo, S; Döhner, K; Arnhardt, I; Kowalik, A; Potter, N; Hwan Kim, DD; Preudhomme, C; Duployez, N; Heuser, M; Valk, PJM;
- Details
- Publication Year 2026-08-13,Volume 148,Issue #7,Page 910-913
- Journal Title
- Blood
- Abstract
- FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.
- Publisher
- Elsevier
- Keywords
- *fms-Like Tyrosine Kinase 3/genetics; Humans; *Leukemia, Myeloid, Acute/genetics/diagnosis; *Neoplasm, Residual/genetics/diagnosis; *Tandem Repeat Sequences; *High-Throughput Nucleotide Sequencing/methods
- Research Division(s)
- Blood Cells and Blood Cancer
- PubMed ID
- 42237660
- Publisher's Version
- https://doi.org/10.1182/blood.2026033569
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2026033569- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-08-28 10:52:06
Last Modified: 2026-08-28 10:56:27